Tue, August 23, 2022
Mon, August 22, 2022
Fri, August 19, 2022
Thu, August 18, 2022
Wed, August 17, 2022
Tue, August 16, 2022

Matthew Sykes Downgraded (TXG) to Strong Sell and Decreased Target to $35 on, Aug 18th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-decreased-target-to-35-on-aug-18th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Sykes of Goldman Sachs, Downgraded "10x Genomics, Inc." (TXG) to Strong Sell and Decreased Target from $55 to $35 on, Aug 18th, 2022.

Matthew has made no other calls on TXG in the last 4 months.



There are 6 other peers that have a rating on TXG. Out of the 6 peers that are also analyzing TXG, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Weinstein of "William Blair" Downgraded from Buy to Hold on, Friday, July 15th, 2022
  • Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $60 on, Thursday, July 14th, 2022


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $70 on, Wednesday, August 10th, 2022
  • Dan Brennan of "Cowen & Co." Maintained at Buy with Decreased Target to $50 on, Friday, July 15th, 2022
  • Derik De Bruin of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $35 on, Friday, July 15th, 2022
  • Patrick Donnelly of "Citigroup" Maintained at Strong Buy with Decreased Target to $100 on, Thursday, May 5th, 2022

Publication Contributing Sources